Freenome, Inc.

PCSC is a blank-check company whose announced business combination targets Freenome, Inc., a South San Francisco-based life sciences company focused on AI-driven early cancer detection through multi-omic blood analysis. The SPAC filed an amended current report on Form 8-K/A with the SEC on August 13, 2026 (accession 0001140361-26-032873), reflecting an update to a previously reported material event associated with the proposed transaction. The deal places PCSC in the healthcare and genomics diagnostics sector, a space that has attracted sustained SPAC attention given the capital intensity of bringing novel liquid-biopsy platforms to clinical and commercial scale. For complete transaction terms, shareholder vote timelines, and target financials, sign up for full data access at SpacDesk.